View On Demand

Lighting A Path To Better Breast Cancer Surgery

About the Event

Currently 30% of the time surgeons perform breast surgery they don’t achieve a complete resection which doubles the risk of recurrence for these patients.

The Lumicell Direct Visualization System includes an imaging agent, device, and software that work together assist surgeons to detect cancerous tissue in real time so they can remove it all the first time. In clinical trials with over 700 patients in sites that include Stanford, MD Anderson, Mass General, Duke, and Cleveland Clinic, surgeons using the Lumicell DVS have demonstrated the ability to remove residual cancer left behind thus enabled a more complete cancer resection for patients.

Lumicell has completed their clinical trials and is in the process of filing a PMA for the device. They expect FDA approval in Q4 2023 with commercial launch in the first quarter of 2024 for Breast Cancer. LUMISIGHT™ is designed to work with all solid tumor cancers making it a platform technology with the potential for expanded indications in the future.  

Join our webinar with Lumicell CEO, Kevin Hershberger, to learn how their technology is lighting the way to better outcomes for breast cancer patients.

View On-Demand


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.